Portal de Periódicos da CAPES

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

2013; Elsevier BV; Volume: 122; Issue: 20 Linguagem: Inglês

10.1182/blood-2013-05-504043

1528-0020

Josée Golay, Fabio Da Roit, Luca Bologna, Claudia Ferrara, Jeanette H.W. Leusen, Alessandro Rambaldi, Christian Klein, Martino Introna,

Immunodeficiency and Autoimmune Disorders

Key Points Phagocytosis of CLL targets by neutrophils is a novel mechanism of action of the glycoengineered anti-CD20 antibody obinutuzumab. This mechanism takes place in physiological conditions and requires CD16B and CD32A.